Artificial Intelligence
Pharmaceutical
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has spent the past decade trying to make the country a more attractive place to develop and launch innovative drugs and biologics. The most visible signal is the Sakigake designation program, which offers priority consultation and a faster review target for eligible products, plus policy incentives that can support earlier market entry. 25 February 2026
Today's issue
Refine search
Biotechnology
US biotech Elephas Biosciences has entered a research collaboration with artificial intelligence firm Mithrl, aiming to combine real-time tumor profiling with automated data analysis to better understand responses to immunotherapy. 17 April 2026
Pharmaceutical
Ryght AI, a provider of real-time generative AI solutions for the clinical research industry, has announced the launch of RyghtSites.com.
The free, publicly accessible tool allows pharmaceutical companies and Contract Research Organizations (CROs) to instantly search, rank, and download lists of the world's best clinical research sites for your search. 17 April 2026
Biotechnology
German innovation hub BioMed X has launched its first research team in France, partnering with French pharma Servier to advance AI-driven antibody engineering at the Paris-Saclay campus. 16 April 2026
Pharmaceutical
Novo Nordisk has announced a strategic partnership with OpenAI, the US AI research and deployment company. 14 April 2026
Biotechnology
Japanese drugmaker Daiichi Sankyo is deepening its push into AI-driven oncology, partnering with USA-based Imagene AI to advance biomarker discovery and response prediction across its cancer pipeline. 10 April 2026
Pharmaceutical
Tempus AI , a technology company leading the adoption of AI to advance precision medicine, has announced an expanded, multi-year collaboration with Gilead Sciences aimed at building and advancing Gilead’s oncology pipeline. 10 April 2026
Biotechnology
Dyno Therapeutics, a privately-held US genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Japan’s Astellas Pharma has exercised its option to license a novel adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle. 8 April 2026
Biotechnology
Syneron Bio, a China based leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31. The news comes less than four months after Syneron closed its Series A and A+ rounds at close to $100 million in total. 7 April 2026
Biotechnology
French biotech company Transgene , which develops virus-based immunotherapies for the treatment of cancer, and NEC Bio, a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, have signed a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer. s 3 April 2026
Biotechnology
Privately-held antibody discovery and design company Infinimmune has announced a collaboration with Merck & Co. 1 April 2026
Biotechnology
OpenProtein.AI, a US firm that calls itself a leader in AI-powered protein engineering software, has announced an expansion of its partnership with privately-held German drugmaker Boehringer Ingelheim to co-develop specialized antibody discovery and optimization workflows. 1 April 2026
Pharmaceutical
Swiss neurotech firm MindMaze Therapeutics and US provider Vibra Healthcare have reported real-world evidence suggesting technology-enabled, high-dose therapy can improve recovery outcomes for stroke patients in inpatient rehabilitation. 31 March 2026
Pharmaceutical
Honk Kong-based Insilico Medicine has announced a drug discovery collaboration with US pharma major Eli Lilly that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. 30 March 2026
Biotechnology
US biotech Pinnacle Medicines, which is pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, today announced the closing of an oversubscribed $89 million Series B financing. 26 March 2026
Pharmaceutical
Israel-based Purple Biotech today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug discovery and development, to accelerate and enhance Purple Biotech's next-generation tri-specific antibody platform leveraging advanced generative AI capabilities. 26 March 2026
Biotechnology
Hong Kong-listed biotech Insilico Medicine has introduced PandaClaw, a new autonomous analysis tool within its PandaOmics platform, as part of a wider shift toward agent-based artificial intelligence systems. 25 March 2026
Pharmaceutical
The global market for artificial intelligence in precision medicine is forecast to expand at a 31.35% CAGR between 2026 and 2032, according to MarkNtel Advisors, as healthcare systems lean further into data-driven care. 25 March 2026
Biotechnology
AI-powered disease detection and care coordination company Viz.ai has announced a partnership with RNAi therapeutics firm Alnylam Pharmaceuticals to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure. 25 March 2026
Pharmaceutical
insitro, a California-based machine-learning driven drug discovery and development company, today announced the expansion of its strategic collaboration with Bristol Myers Squibb to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). 23 March 2026
Biotechnology
US biotech startup PerturbAI has emerged from stealth with what it describes as the largest in vivo CRISPR atlas to date, a dataset spanning 8 million brain-wide cells aimed at mapping gene function directly in living tissue. 18 March 2026
Biotechnology
US biotech Elephas Biosciences has entered a research collaboration with artificial intelligence firm Mithrl, aiming to combine real-time tumor profiling with automated data analysis to better understand responses to immunotherapy. 17 April 2026
Pharmaceutical
Ryght AI, a provider of real-time generative AI solutions for the clinical research industry, has announced the launch of RyghtSites.com.
The free, publicly accessible tool allows pharmaceutical companies and Contract Research Organizations (CROs) to instantly search, rank, and download lists of the world's best clinical research sites for your search. 17 April 2026
Biotechnology
German innovation hub BioMed X has launched its first research team in France, partnering with French pharma Servier to advance AI-driven antibody engineering at the Paris-Saclay campus. 16 April 2026
Pharmaceutical
Novo Nordisk has announced a strategic partnership with OpenAI, the US AI research and deployment company. 14 April 2026
Biotechnology
Japanese drugmaker Daiichi Sankyo is deepening its push into AI-driven oncology, partnering with USA-based Imagene AI to advance biomarker discovery and response prediction across its cancer pipeline. 10 April 2026
Pharmaceutical
Tempus AI , a technology company leading the adoption of AI to advance precision medicine, has announced an expanded, multi-year collaboration with Gilead Sciences aimed at building and advancing Gilead’s oncology pipeline. 10 April 2026
Biotechnology
Dyno Therapeutics, a privately-held US genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Japan’s Astellas Pharma has exercised its option to license a novel adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle. 8 April 2026
Biotechnology
Syneron Bio, a China based leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31. The news comes less than four months after Syneron closed its Series A and A+ rounds at close to $100 million in total. 7 April 2026
Biotechnology
French biotech company Transgene , which develops virus-based immunotherapies for the treatment of cancer, and NEC Bio, a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, have signed a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer. s 3 April 2026
Biotechnology
Privately-held antibody discovery and design company Infinimmune has announced a collaboration with Merck & Co. 1 April 2026
Biotechnology
OpenProtein.AI, a US firm that calls itself a leader in AI-powered protein engineering software, has announced an expansion of its partnership with privately-held German drugmaker Boehringer Ingelheim to co-develop specialized antibody discovery and optimization workflows. 1 April 2026
Pharmaceutical
Swiss neurotech firm MindMaze Therapeutics and US provider Vibra Healthcare have reported real-world evidence suggesting technology-enabled, high-dose therapy can improve recovery outcomes for stroke patients in inpatient rehabilitation. 31 March 2026
Pharmaceutical
Honk Kong-based Insilico Medicine has announced a drug discovery collaboration with US pharma major Eli Lilly that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. 30 March 2026
Biotechnology
US biotech Pinnacle Medicines, which is pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, today announced the closing of an oversubscribed $89 million Series B financing. 26 March 2026
Pharmaceutical
Israel-based Purple Biotech today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug discovery and development, to accelerate and enhance Purple Biotech's next-generation tri-specific antibody platform leveraging advanced generative AI capabilities. 26 March 2026
Biotechnology
Hong Kong-listed biotech Insilico Medicine has introduced PandaClaw, a new autonomous analysis tool within its PandaOmics platform, as part of a wider shift toward agent-based artificial intelligence systems. 25 March 2026
Pharmaceutical
The global market for artificial intelligence in precision medicine is forecast to expand at a 31.35% CAGR between 2026 and 2032, according to MarkNtel Advisors, as healthcare systems lean further into data-driven care. 25 March 2026
Biotechnology
AI-powered disease detection and care coordination company Viz.ai has announced a partnership with RNAi therapeutics firm Alnylam Pharmaceuticals to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure. 25 March 2026
Pharmaceutical
insitro, a California-based machine-learning driven drug discovery and development company, today announced the expansion of its strategic collaboration with Bristol Myers Squibb to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). 23 March 2026
Biotechnology
US biotech startup PerturbAI has emerged from stealth with what it describes as the largest in vivo CRISPR atlas to date, a dataset spanning 8 million brain-wide cells aimed at mapping gene function directly in living tissue. 18 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze